MDCX
Medicus Pharma Ltd.
Healthcare — Drug Manufacturers - General
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.
Price History
Fundamentals
| Market Cap | $22.66M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.83 |
| EPS (TTM) | $-2.63 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -2865.18% |
| Debt/Equity | 177.50 |
| Recommendation | None |
| Analyst Target | $5.67 |
| Analysts | 3 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 60.8 |
| Beta | -0.50 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.69 |
| 52-Week Low | $0.25 |
| 50-Day Avg | $0.34 |
| 200-Day Avg | $1.27 |
| Avg Volume | $2.12M |
| Volume | 582.7K |
Performance Analysis
BULLISHMDCX shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:19 UTC
Back to Screener Export Report